Abstract: A radio frequency (RF) weak magnetic field detection sensor includes a ferromagnetic core, a pickup coil disposed to surround the ferromagnetic core, a substrate that includes an opening, a core pad connected to the ferromagnetic core and a coil pad connected to the pickup coil, and an insulating tube interposed between the ferromagnetic core and the pickup coil. The insulating tube includes a bobbin around which the pickup coil is wound, and a core hole formed to pass through the bobbin and configured to accommodate the ferromagnetic core.

Abstract: An apparatus and method for transmitting and receiving magnetic field signals in a magnetic field communication system are provided. The apparatus includes a controller configured to generate a communication signal, matching units that are configured to receive the communication signal and that respectively correspond to different matching frequencies, and loop antennas that are connected to the matching units, respectively, and that are configured to convert communication signals according to the different matching frequencies into magnetic transmission signals in the form of magnetic field energy and to transmit the magnetic transmission signals.

Abstract: A light-scattering dust sensor includes: a light scattering region; a light emitter configured to emit light to the light scattering region; a light receiver configured to receive scattered light generated in the light scattering region; and an emitted light limiter located between the light emitter and the light scattering region, wherein the light emitted by the light emitter includes: peripheral light; and central light having an intensity that is more uniform than an intensity of the peripheral light, wherein the emitted light limiter is configured to block part of the emitted light, wherein the part of the emitted light blocked by the emitted light limiter includes the peripheral light.

Abstract: The present inventors screened peptides having a specific sequence specifically binding to amyloid-beta antibody and accordingly confirmed that A?22(pE)-42 peptide showed higher reactivity to amyloid-beta antibody in serum of Alzheimer's disease patients. Therefore, the said A?22(pE)-42 peptide can be used as an active ingredient for the kit for diagnosing dementia and thus it can be said that the peptide can be effectively used for the diagnosis of dementia whose early diagnosis is hardly possible.